Australian Biotechnologies

SERVICES

Corporate Advisory, Corporate Strategy, R&DTI, Government, Grants, Bids & Tenders.

YEAR

2015 — 2019

 
Corporate Advisory
Accounting & Taxation
Grants, Bids & Tenders

Australian Biotechnologies is focused on bettering life enhancing medical products for the Australian community.

Throughout their 16 years of operating, Australian Biotechnologies has successfully introduced and launched numerous new allograft and biologic products, and to date has supplied over 30,000 allografts to the Australian community. As part of their vision, Australian Biotechnologies required a strategy plan to ensure their R&D program was the best in the space to meet their business mission statement. 

In 2015, Mark Bouw Group was tasked with developing and implementing a R&D data management strategy. Initially, Mark Bouw Group assisted with the R&D strategy plan and has since worked closely with the Australian Biotechnologies R&D team and key executives, ensuring that all are well versed with our R&D activities and business plans whilst continuing to provide expert advice. 

“Mark Bouw Group has a world class strategy tool kit that continuously adds value to our organisation. We consider Mark Bouw Group as a core advisory partner.”

- Simon Berry, CEO at Australian Biotechnologies Pty Ltd, Sydney AUS

An outcome of our R&D data management platform has been our success in achieving approved R&D activity status with the Australian Government’s  Department of Industry, Science, Energy and Resources since 2015, with the Mark Bouw Group working closely with our internal team and registered Tax Agent at all steps across the data collection and reporting process.  Mark Bouw Group has provided support with an AASB138 review of development costs.

Additionally, Mark Bouw Group has assisted our organisation with offshore go-to-market analysis during 2017 & 2019, and a R&D data management strategy for our JV, Origin Biologics based in Nevada, USA.